Jamieson is pleased to announce it has advised the management team of Sweden based Immedica as part of KKR’s investment in the business. Existing shareholder Impilo, a Nordic healthcare investment firm, will continue as a significant shareholder alongside KKR.

Immedica, headquartered in Sweden, is a pharmaceutical company focused on the commercialisation of medicines for rare diseases and specialty care products. Through this transaction, Impilo and KKR will support the continued long-term strategic growth of the business going forward including the launch of additional pipeline assets, in-licencing and M&A.

Anders Edvell, CEO of Immedica commented:

“Jamieson were an invaluable support to the senior leadership team throughout the process. They had a strong understanding of the market and helped to deliver a great outcome for the team and to ensure a smooth process.”

Stephen Maxwell, Gus Gayford, Jack Henshall and Helen Briscoe advised Anders Edvell and the management team of Immedica on the shareholding and incentive arrangements as part of the transaction.